No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Amgen’s Aflibercept Biosimilars Receive Positive CHMP Opinions
On 30 January 2025, Amgen’s Pavblu® and Skojoy®, biosimilars to Regeneron/Bayer’s Eylea® (aflibercept), received positive recommendations for marketing approval from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The two biosimilars are indicated for nAMD and visual impairment due to: macular oedema secondary to retinal vein occlusion (branch RVO or central